Search Results 1741-1750 of 15589 for Orange Peel tea

1. Throat cancer - Doctors and departments - Mayo Clinic

   ... Skin cancer, Squamous cell carcinoma of the skin, Sarcoma, Paraganglioma, Schwannoma, Adenoid cystic carcinoma, Salivary gland tumor, Nasopharyngeal ...

2. General Internal Medicine - Clinical trials

   This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical ...

3. Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System For Newly Diagnosed Glioblastoma - Mayo Clinic

   This study is evaluating an experimental treatment for glioblastoma that uses an investigational drug (5-ALA) combined with a non-invasive ultrasound device ( ...

4. Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells to Treat Painful Lumbar Facet Joint Arthropathies - Mayo Clinic

   The purpose of this study is to determine the safety and preliminary effectiveness of allogeneic, culture-expanded BM-MSCs in subjects with painful facet joint ...

5. Lintuzumab-Ac225 In Older Acute Myeloid Leukemia (AML) Patients - Mayo Clinic

   Active malignancy within 2 years of entry, except previously treated non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, and ...

6. Study Of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens In Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma - Mayo Clinic

   History of any second malignancy in the last 3 years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible.

7. Irinotecan And Cetuximab With Or Without Bevacizumab In Treating Patients With RAS Wild-Type Locally Advanced Or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery - Mayo Clinic

   Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, ...

8. A Phase 1 Dose Escalation And Expansion Study Of TGR-1202 + Ruxolitinib In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, Or Polycythemia Vera Resistant To Hydroxyurea - Mayo Clinic

   A Phase 1 Dose Escalation And Expansion Study Of TGR-1202 + Ruxolitinib In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), ...

9. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM) - Mayo Clinic

   ... skin changes) or Primary Plasma Cell Leukemia (defined as circulating plasma cells \>5%). 2. Prior systemic therapy for multiple myeloma, or smoldering ...

10. A Study Evaluating Tolerability And Efficacy Of Navitoclax In Combination With Ruxolitinib In Subjects With Myelofibrosis - Mayo Clinic

    Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin;; Asymptomatic prostate cancer without known metastatic disease and ...